Merck (MRK) Construction in Progress (2009 - 2025)
Merck (MRK) reported Construction in Progress of $9.2 billion for Q4 2025, up 14.8% year-over-year from $8.0 billion in Q4 2024, and up 14.8% quarter-over-quarter from $8.0 billion in Q4 2024.
Merck (MRK) Construction in Progress (2009 - 2025) Analysis & Trends
Merck (MRK) has 17 years of Construction in Progress data on file, last reported at $9.2 billion in Q4 2025.
- Construction in Progress for Q4 2025 came in at $9.2 billion, up 14.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.2 billion (up 14.8% YoY), and the FY2025 annual result was $9.2 billion, up 14.8% from the prior year.
- Construction in Progress improved to $9.2 billion in Q4 2025 per MRK's latest filing, from $8.0 billion in the prior quarter.
- Over five years, Construction in Progress peaked at $9.2 billion in Q4 2022 and troughed at $8.0 billion in Q4 2024.
- A 5-year average of $8.6 billion and a median of $8.3 billion in 2021 frame the typical range for Construction in Progress.
- The sharpest annual moves came in 2021 and 2023: Construction in Progress rose 19.3% in 2021, then retreated 10.06% in 2023.
- A 5-year view of Construction in Progress shows it stood at $8.3 billion in 2021, then increased by 10.5% to $9.2 billion in 2022, then retreated by 10.06% to $8.3 billion in 2023, then retreated by 3.36% to $8.0 billion in 2024, then increased by 14.8% to $9.2 billion in 2025.
- Business Quant data shows MRK's Construction in Progress at $9.2 billion in Q4 2025, $8.0 billion in Q4 2024, and $8.3 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 7.98 Bn |
| Dec 31, 2023 | 8.26 Bn |
| Dec 31, 2022 | 9.19 Bn |
| Dec 31, 2021 | 8.31 Bn |
| Dec 31, 2020 | 6.97 Bn |
| Dec 31, 2019 | 5.01 Bn |
| Dec 31, 2018 | 3.36 Bn |
| Dec 31, 2017 | 2.30 Bn |
| Dec 31, 2016 | 1.87 Bn |
| Dec 31, 2015 | 1.53 Bn |
| Dec 31, 2014 | 1.45 Bn |
| Dec 31, 2013 | 1.81 Bn |
| Dec 31, 2012 | 2.44 Bn |
| Dec 31, 2011 | 2.20 Bn |
| Dec 31, 2010 | 2.07 Bn |
| Dec 31, 2009 | 1.82 Bn |